1
|
Kirby J, Chester K. Automation to facilitate optimisation of breast radiotherapy treatments using EPID-based in vivodosimetry. Phys Med Biol 2024; 69:095018. [PMID: 38537296 DOI: 10.1088/1361-6560/ad387e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Accepted: 03/26/2024] [Indexed: 04/25/2024]
Abstract
Objective. To use automation to facilitate the monitoring of each treatment fraction using an electronic portal imaging device (EPID) basedin vivodosimetry (IVD) system, allowing optimisation of breast radiotherapy delivery for individual patients and cohorts.Approach. A suite of in-house software was developed to reduce the number of manual interactions with the commercial IVD system, dosimetry check. An EPID specific pixel sensitivity map facilitated use of the EPID panel away from the central axis. Point dose difference and the change in standard deviation in dose were identified as useful dose metrics, with standard deviation used in preference to gamma in the presence of a systematic dose offset. Automated IVD was completed for 3261 fractions across 704 patients receiving breast radiotherapy.Main results. Multiple opportunities for treatment optimisation were identified for individual patients and across patient cohorts as a result of successful implementation of automated IVD. 5.1% of analysed fractions were out of tolerance with 27.1% of these considered true positives. True positive results were obtained on any fraction of treatment and if IVD had only been completed on the first fraction, 84.4% of true positive results would have been missed. This was made possible due to the automation that saved over 800 h of manual intervention and stored data in an accessible database.Significance. An improved EPID calibration to allow off-axis measurement maximises the number of patients eligible for IVD (36.8% of patients in this study). We also demonstrate the importance in selecting context-specific assessment metrics and how these can lead to a managable false positive rate. We have shown that the use of fully automated IVD facilitates use on every fraction of treatment. This leads to identification of areas for treatment improvement for both individuals and across a patient cohort, expanding the uses of IVD from simply gross error detection towards treatment optimisation.
Collapse
Affiliation(s)
- Joshua Kirby
- Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, United Kingdom
| | - Katherine Chester
- Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Cumberland Infirmary, United Kingdom
| |
Collapse
|
2
|
Dogan N, Mijnheer BJ, Padgett K, Nalichowski A, Wu C, Nyflot MJ, Olch AJ, Papanikolaou N, Shi J, Holmes SM, Moran J, Greer PB. AAPM Task Group Report 307: Use of EPIDs for Patient-Specific IMRT and VMAT QA. Med Phys 2023; 50:e865-e903. [PMID: 37384416 PMCID: PMC11230298 DOI: 10.1002/mp.16536] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Revised: 04/23/2023] [Accepted: 05/15/2023] [Indexed: 07/01/2023] Open
Abstract
PURPOSE Electronic portal imaging devices (EPIDs) have been widely utilized for patient-specific quality assurance (PSQA) and their use for transit dosimetry applications is emerging. Yet there are no specific guidelines on the potential uses, limitations, and correct utilization of EPIDs for these purposes. The American Association of Physicists in Medicine (AAPM) Task Group 307 (TG-307) provides a comprehensive review of the physics, modeling, algorithms and clinical experience with EPID-based pre-treatment and transit dosimetry techniques. This review also includes the limitations and challenges in the clinical implementation of EPIDs, including recommendations for commissioning, calibration and validation, routine QA, tolerance levels for gamma analysis and risk-based analysis. METHODS Characteristics of the currently available EPID systems and EPID-based PSQA techniques are reviewed. The details of the physics, modeling, and algorithms for both pre-treatment and transit dosimetry methods are discussed, including clinical experience with different EPID dosimetry systems. Commissioning, calibration, and validation, tolerance levels and recommended tests, are reviewed, and analyzed. Risk-based analysis for EPID dosimetry is also addressed. RESULTS Clinical experience, commissioning methods and tolerances for EPID-based PSQA system are described for pre-treatment and transit dosimetry applications. The sensitivity, specificity, and clinical results for EPID dosimetry techniques are presented as well as examples of patient-related and machine-related error detection by these dosimetry solutions. Limitations and challenges in clinical implementation of EPIDs for dosimetric purposes are discussed and acceptance and rejection criteria are outlined. Potential causes of and evaluations of pre-treatment and transit dosimetry failures are discussed. Guidelines and recommendations developed in this report are based on the extensive published data on EPID QA along with the clinical experience of the TG-307 members. CONCLUSION TG-307 focused on the commercially available EPID-based dosimetric tools and provides guidance for medical physicists in the clinical implementation of EPID-based patient-specific pre-treatment and transit dosimetry QA solutions including intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) treatments.
Collapse
Affiliation(s)
- Nesrin Dogan
- Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - Ben J Mijnheer
- Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Kyle Padgett
- Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - Adrian Nalichowski
- Department of Radiation Oncology, Karmanos Cancer Institute, Detroit, Michigan, USA
| | - Chuan Wu
- Department of Radiation Oncology, Sutter Medical Foundation, Roseville, California, USA
| | - Matthew J Nyflot
- Department of Radiation Oncology, University of Washington, Seattle, Washington, USA
| | - Arthur J Olch
- Department of Radiation Oncology, University of Southern California, and Children's Hospital Los Angeles, Los Angeles, California, USA
| | - Niko Papanikolaou
- Division of Medical Physics, UT Health-MD Anderson, San Antonio, Texas, USA
| | - Jie Shi
- Sun Nuclear Corporation - A Mirion Medical Company, Melbourne, Florida, USA
| | | | - Jean Moran
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Peter B Greer
- Department of Radiation Oncology, Calvary Mater Newcastle Hospital, Newcastle, NSW, Australia
- School of Information and Physical Sciences, University of Newcastle, Newcastle, NSW, Australia
| |
Collapse
|
3
|
Olaciregui-Ruiz I, Osinga-Blaettermann JM, Ortega-Marin K, Mijnheer B, Mans A. Extending in aqua portal dosimetry with dose inhomogeneity conversion maps for accurate patient dose reconstruction in external beam radiotherapy. Phys Imaging Radiat Oncol 2022; 22:20-27. [PMID: 35493851 PMCID: PMC9038561 DOI: 10.1016/j.phro.2022.04.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 04/07/2022] [Accepted: 04/08/2022] [Indexed: 11/24/2022] Open
|
4
|
Fiagan YA, Bossuyt E, Nevens D, Dirix P, Theys F, Gevaert T, Verellen D. In vivo dosimetry for patients with prostate cancer to assess possible impact of bladder and rectum preparation. Tech Innov Patient Support Radiat Oncol 2020; 16:65-69. [PMID: 33294646 PMCID: PMC7701258 DOI: 10.1016/j.tipsro.2020.10.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 10/28/2020] [Accepted: 10/29/2020] [Indexed: 11/19/2022] Open
Abstract
PURPOSE/OBJECTIVE In all treatment sites of our radiotherapy network, in vivo dosimetry (PerFRACTION™) was fully implemented in February 2018. We hypothesized that additional help with bladder and rectum preparation by home nursing would improve patients' preparation and investigated if this could be assessed using in vivo dosimetry (IVD). MATERIALS/METHODS A retrospective study was conducted with a test group who received additional help with bladder and rectum preparation by home nurses and a control group who only received information on bladder and rectum preparation according to the standard protocol. Patients were treated with a 6 MV Volumetric Modulated Arc Therapy (VMAT) technique. Electronic portal imaging device (EPID)-based integrated transit dose images were acquired on the first 3 days of treatment and weekly thereafter or more if failed fractions (FF) occurred. Results were analyzed using a global gamma analysis with a threshold of 20%, tolerance of 5% (dose difference) and 5 mm (distance to agreement), and a passing level of 95%. RESULTS Data of 462 prostate patients was analyzed: 39 and 423 in a test and control group respectively with a comparable number of measurements (on average 8.0 (σ = 4.8) and 7.1 (σ = 4.5) respectively per treatment course). Of the FF, 39% and 31% were related to variations in bladder and rectum filling for the test and control group respectively. Subgroups were created based on the number of FF, no statistically significant differences were observed. CONCLUSION Two dimensional EPID-based IVD successfully detected deviations due to variations in bladder and rectum filling, however it could not confirm the hypothesis.
Collapse
Affiliation(s)
- Yawo A.C. Fiagan
- Iridium Netwerk, Radiation Oncology Department, Universiteit Antwerpen, Antwerp, Belgium
- Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium
| | - Evy Bossuyt
- Iridium Netwerk, Radiation Oncology Department, Universiteit Antwerpen, Antwerp, Belgium
| | - Daan Nevens
- Iridium Netwerk, Radiation Oncology Department, Universiteit Antwerpen, Antwerp, Belgium
- Faculty of Medicine and Health Sciences, Universiteit Antwerpen, Antwerp, Belgium
| | - Piet Dirix
- Iridium Netwerk, Radiation Oncology Department, Universiteit Antwerpen, Antwerp, Belgium
- Faculty of Medicine and Health Sciences, Universiteit Antwerpen, Antwerp, Belgium
| | - Frank Theys
- Iridium Netwerk, Radiation Oncology Department, Universiteit Antwerpen, Antwerp, Belgium
| | - Thierry Gevaert
- Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium
| | - Dirk Verellen
- Iridium Netwerk, Radiation Oncology Department, Universiteit Antwerpen, Antwerp, Belgium
- Faculty of Medicine and Health Sciences, Universiteit Antwerpen, Antwerp, Belgium
| |
Collapse
|
5
|
Olaciregui-Ruiz I, Beddar S, Greer P, Jornet N, McCurdy B, Paiva-Fonseca G, Mijnheer B, Verhaegen F. In vivo dosimetry in external beam photon radiotherapy: Requirements and future directions for research, development, and clinical practice. Phys Imaging Radiat Oncol 2020; 15:108-116. [PMID: 33458335 PMCID: PMC7807612 DOI: 10.1016/j.phro.2020.08.003] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 08/17/2020] [Accepted: 08/18/2020] [Indexed: 11/18/2022] Open
Abstract
External beam radiotherapy with photon beams is a highly accurate treatment modality, but requires extensive quality assurance programs to confirm that radiation therapy will be or was administered appropriately. In vivo dosimetry (IVD) is an essential element of modern radiation therapy because it provides the ability to catch treatment delivery errors, assist in treatment adaptation, and record the actual dose delivered to the patient. However, for various reasons, its clinical implementation has been slow and limited. The purpose of this report is to stimulate the wider use of IVD for external beam radiotherapy, and in particular of systems using electronic portal imaging devices (EPIDs). After documenting the current IVD methods, this report provides detailed software, hardware and system requirements for in vivo EPID dosimetry systems in order to help in bridging the current vendor-user gap. The report also outlines directions for further development and research. In vivo EPID dosimetry vendors, in collaboration with users across multiple institutions, are requested to improve the understanding and reduce the uncertainties of the system and to help in the determination of optimal action limits for error detection. Finally, the report recommends that automation of all aspects of IVD is needed to help facilitate clinical adoption, including automation of image acquisition, analysis, result interpretation, and reporting/documentation. With the guidance of this report, it is hoped that widespread clinical use of IVD will be significantly accelerated.
Collapse
Affiliation(s)
- Igor Olaciregui-Ruiz
- Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Sam Beddar
- Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Peter Greer
- Calvary Mater Newcastle Hospital and University of Newcastle, Newcastle, New South Wales, Australia
| | - Nuria Jornet
- Servei de Radiofísica i Radioprotecció, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Boyd McCurdy
- Medical Physics Department, CancerCare Manitoba, Winnipeg, Manitoba, Canada
| | - Gabriel Paiva-Fonseca
- Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, the Netherlands
| | - Ben Mijnheer
- Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Frank Verhaegen
- Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, the Netherlands
| |
Collapse
|